Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NPS Pharmaceuticals has signed a new agreement with British drug maker GlaxoSmithKline (GSK), replacing their previous research and licensing deal signed in 1993.
Subscribe to our email newsletter
Under the new deal, NPS will be responsible for filing applications for two of GSK’s experimental calcilytic compounds, SB-423557 and SB-423562 (NPSP790 and NPSP795).
The new agreement will widen the licensed field of research for osteoporosis drug ronacaleret, which was co-discovered by both the firms under 1993 pact.
GSK will develop, manufacture and commercialize ronacaleret and will pay development milestones and royalties on any future sales of ronacaleret to NPS.
GSK will no longer have rights to other calcilytic compounds discovered or developed under the 1993 agreement.
NPS president and CEO Francois Nader said this deal is complementary to their late-stage pipeline, which already includes a Phase 3 compound in development for the rare endocrine disorder hypoparathyroidism.